Molecular modelling of trimethoprim complexes of human wild-type and mutant dihydrofolate reductases: Identification of two subsets of binding residues in the antifolate binding site

被引:0
作者
Pan, R
Bowen, D
Southerland, WM
机构
[1] Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA
[2] Howard Univ, Coll Med, Dept Pharmacol, Washington, DC 20059 USA
关键词
antifolate resistance; binding energies; dihydrofolate reductase; trimethoprim;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Computer-assisted molecular modelling was used to generate structures for the trimethoprim (TMP):NADPH:dihydrofolate reductase (DHFR) ternary complexes for human wild-type DHFR and for five DHFR mutants (L22R, L22F,F31S, F31W and Q35P). The mutants correspond to DHFR proteins that have been isolated from tissues exposed to chronic or high dose methotrexate (MTX) and show decreased sensitivity to antifolate inhibition. Analysis of the TMP:DHFR interactions suggest the presence of two subsets of TMP binding residues in the DHFR antifolate binding site. One subset of these residues (GLU30, PHE34, ILE60 and VAL115) are common to each DHFR complex studied and are referred to as core residues. The other TMP binding residues vary among the DHFR complexes studied and are referred to as noncore residues. The core residues exhibit a greater number of TMP contacts/residue and form more stable TMP interactions than noncore residues. Additionally, the core and noncore residues make contact with different regions of the TMP structure. information presented here provides additional insight into the design of new agents for the improved inhibition of wild-type DHFR and the simultaneous inhibition of both wild-type and mutant DHFR molecules. Copyright (C) 1999 John Wiley & Sons, Ltd.
引用
收藏
页码:335 / 340
页数:8
相关论文
共 39 条
[21]  
MATTHEWS DA, 1985, J BIOL CHEM, V260, P392
[22]  
MCIVOR RS, 1990, NUCLEIC ACIDS RES, V18, P7025, DOI 10.1093/nar/18.23.7025
[23]   Rational drug design approach for overcoming drug resistance: Application to pyrimethamine resistance in malaria [J].
McKie, JH ;
Douglas, KT ;
Chan, C ;
Roser, SA ;
Yates, R ;
Read, M ;
Hyde, JE ;
Dascombe, MJ ;
Yuthavong, Y ;
Sirawaraporn, W .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (09) :1367-1370
[24]  
MELERA PW, 1982, J BIOL CHEM, V257, P2939
[25]   PHENOTYPIC-EXPRESSION IN ESCHERICHIA-COLI AND NUCLEOTIDE-SEQUENCE OF 2 CHINESE-HAMSTER LUNG CELL CDNAS ENCODING DIFFERENT DIHYDROFOLATE REDUCTASES [J].
MELERA, PW ;
DAVIDE, JP ;
HESSION, CA ;
SCOTTO, KW .
MOLECULAR AND CELLULAR BIOLOGY, 1984, 4 (01) :38-48
[26]   EXPRESSION OF VARIANT DIHYDROFOLATE-REDUCTASE WITH DECREASED BINDING-AFFINITY TO ANTIFOLATES IN MOLT-3 HUMAN LEUKEMIA-CELL LINES RESISTANT TO TRIMETREXATE [J].
MIYACHI, H ;
TAKEMURA, Y ;
KOBAYASHI, H ;
ANDO, Y .
CANCER LETTERS, 1995, 88 (01) :93-99
[27]   SATURATION MUTAGENESIS AT DIHYDROFOLATE-REDUCTASE CODON-22 AND CODON-31 - A VARIETY OF AMINO-ACID SUBSTITUTIONS CONFERRING METHOTREXATE RESISTANCE [J].
MORRIS, JA ;
MCIVOR, RS .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (07) :1207-1220
[28]   CRITICAL ROLE OF PHENYLALANINE-34 OF HUMAN DIHYDROFOLATE-REDUCTASE IN SUBSTRATE AND INHIBITOR BINDING AND IN CATALYSIS [J].
NAKANO, T ;
SPENCER, HT ;
APPLEMAN, JR ;
BLAKLEY, RL .
BIOCHEMISTRY, 1994, 33 (33) :9945-9952
[29]   MEFLOQUINE - A REVIEW OF ITS ANTIMALARIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY [J].
PALMER, KJ ;
HOLLIDAY, SM ;
BROGDEN, RN .
DRUGS, 1993, 45 (03) :430-475
[30]  
SCHWEITZER BI, 1989, J BIOL CHEM, V264, P20786